Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$1.60 USD
-0.03 (-1.84%)
Updated Apr 24, 2024 04:00 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Plus Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 18 | 18 | 8 | 18 |
Receivables | 0 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 4 | 1 | 1 | 1 |
Total Current Assets | 10 | 22 | 20 | 9 | 20 |
Net Property & Equipment | 1 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 11 | 24 | 22 | 12 | 23 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 10 | 4 | 2 | 3 |
Current Portion Long-Term Debt | 4 | 2 | 2 | 6 | 11 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 11 | 12 | 6 | 9 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 4 | 5 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 2 | 0 | 0 | 7 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 13 | 17 | 11 | 9 | 22 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 479 | 474 | 458 | 437 | 426 |
Retained Earnings | -481 | -467 | -447 | -434 | -425 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -1 | 6 | 11 | 3 | 1 |
Total Liabilities & Shareholder's Equity | 11 | 24 | 22 | 12 | 23 |
Total Common Equity | -1 | 6 | 11 | 3 | 1 |
Shares Outstanding | 4.50 | 2.20 | 1.00 | 0.40 | 0.20 |
Book Value Per Share | -0.30 | 2.93 | 10.84 | 7.58 | 5.80 |
Fiscal Year End for Plus Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 9 | 11 | 11 | 13 |
Receivables | NA | 0 | 0 | 1 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 0 | 1 | 1 |
Total Current Assets | NA | 10 | 12 | 12 | 14 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 11 | 13 | 14 | 16 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 6 | 7 | 7 |
Current Portion Long-Term Debt | NA | 4 | 4 | 5 | 5 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 1 |
Total Current Liabilities | NA | 11 | 11 | 11 | 13 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 13 | 11 | 12 | 13 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 479 | 479 | 476 | 475 |
Retained Earnings | NA | -481 | -477 | -473 | -472 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -1 | 3 | 3 | 3 |
Total Liabilities & Shareholder's Equity | NA | 11 | 13 | 14 | 16 |
Total Common Equity | 0 | -1 | 3 | 3 | 3 |
Shares Outstanding | 4.20 | 4.50 | 4.50 | 2.80 | 2.40 |
Book Value Per Share | 0.00 | -0.30 | 0.58 | 0.95 | 1.12 |